永和股份(605020.SH)首日上市封板 僅成交288萬元 換手率0.43%
格隆匯7月9日丨永和股份今日首日上市,發行價格為6.93元,收漲44.01%報9.98元,全天僅成交288萬元,換手率0.43%,市值27億元。永和股份作為一家集螢石資源、氫氟酸、單質及混合氟碳化學品、含氟高分子材料的研發、生產和銷售為一體的氟化工領軍企業之一,是我國氟化工行業中產業鏈最完整的企業之一。公司核心業務是氟碳化學品,目前,氟碳化學品收入成為公司重要的業績增長動力,2018年至2020年佔比分別為81.14%、76.15%、63.52%。公司的含氟高分子材料收入逐年增長,銷售金額佔比常年位於12%至24%之間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.